Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Michaelis

Showing results (171-180 of 214) with videos related to

Pageof 22
Sort By:
Cells|April 3, 2021
Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell LineHisham Saafan, Ahmad Alahdab, Robin Michelet, et al.
Cells|April 25, 2025
Artesunate Inhibits Metastatic Potential in Cisplatin-Resistant Bladder Cancer Cells by Altering IntegrinsOlesya Vakhrusheva, Fuguang Zhao, Sascha Dennis Markowitsch, et al.
Communications Biology|June 26, 2020
SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabineTamara Rothenburger, Katie-May McLaughlin, Tobias Herold, et al.
Cells|October 5, 2019
Intact-Cell MALDI-ToF Mass Spectrometry for the Authentication of Drug-Adapted Cancer Cell LinesJane F Povey, Emily Saintas, Adewale V Aderemi, et al.
Biochemical Pharmacology|August 25, 2009
Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell linesMartin Michaelis, Malte C Kleinschmidt, Susanne Barth, et al.
Cancers|March 6, 2021
Shikonin Reduces Growth of Docetaxel-Resistant Prostate Cancer Cells Mainly through NecroptosisSascha D Markowitsch, Kira M Juetter, Patricia Schupp, et al.
International Journal of Clinical Pharmacology and Therapeutics|November 13, 2013
A systems pharmacology approach to improve drug therapy in NSCLC: establishing a CESAR networkGanna V Kalayda, Martin Michaelis, Jindrich Cinatl, et al.
Translational Oncology|January 28, 2014
Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of DrugsNadine Löschmann, Martin Michaelis, Florian Rothweiler, et al.
International Journal of Clinical Pharmacology and Therapeutics|November 14, 2013
NSCLC cells adapted to EGFR inhibition accumulate EGFR interacting proteins and down-regulate microRNA related to epithelial-mesenchymal transitionRobert M Mader, Sarah Foerster, Navin Sarin, et al.
Biomaterials|December 25, 2009
Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticlesSylvia Wagner, Florian Rothweiler, Marion G Anhorn, et al.
Pageof 22

Showing results (171-180 of 214) with videos related to

Sort By:
Pageof 22
Cells|April 3, 2021
Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell LineHisham Saafan, Ahmad Alahdab, Robin Michelet, et al.
Cells|April 25, 2025
Artesunate Inhibits Metastatic Potential in Cisplatin-Resistant Bladder Cancer Cells by Altering IntegrinsOlesya Vakhrusheva, Fuguang Zhao, Sascha Dennis Markowitsch, et al.
Communications Biology|June 26, 2020
SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabineTamara Rothenburger, Katie-May McLaughlin, Tobias Herold, et al.
Cells|October 5, 2019
Intact-Cell MALDI-ToF Mass Spectrometry for the Authentication of Drug-Adapted Cancer Cell LinesJane F Povey, Emily Saintas, Adewale V Aderemi, et al.
Biochemical Pharmacology|August 25, 2009
Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell linesMartin Michaelis, Malte C Kleinschmidt, Susanne Barth, et al.
Cancers|March 6, 2021
Shikonin Reduces Growth of Docetaxel-Resistant Prostate Cancer Cells Mainly through NecroptosisSascha D Markowitsch, Kira M Juetter, Patricia Schupp, et al.
International Journal of Clinical Pharmacology and Therapeutics|November 13, 2013
A systems pharmacology approach to improve drug therapy in NSCLC: establishing a CESAR networkGanna V Kalayda, Martin Michaelis, Jindrich Cinatl, et al.
Translational Oncology|January 28, 2014
Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of DrugsNadine Löschmann, Martin Michaelis, Florian Rothweiler, et al.
International Journal of Clinical Pharmacology and Therapeutics|November 14, 2013
NSCLC cells adapted to EGFR inhibition accumulate EGFR interacting proteins and down-regulate microRNA related to epithelial-mesenchymal transitionRobert M Mader, Sarah Foerster, Navin Sarin, et al.
Biomaterials|December 25, 2009
Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticlesSylvia Wagner, Florian Rothweiler, Marion G Anhorn, et al.
Pageof 22